Study S002031

Impact of GLP1-RAs on Inflammation and Endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07314684
Acronym: STABLE-GLP1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 80
Start: 2025-09-08
Primary completion: 2027-03-08
Lead sponsor: Federico II University
Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: DRUG:semaglutide; DRUG:Standard Treatment (Guideline-Based)
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2025-520802-37-00; NIH:2025

Registered primary outcomes

To evaluate the effects of semaglutide in addition to standard therapy on inflammatory biomarkers compared with standard therapy alone in T2DM patients without ASCVD or severe TOD but with SCORE2-Diabetes ≥10%. [From enrollment to the end of treatment at 52 weeks]
To evaluate the effects of semaglutide in addition to standard therapy on biomarkers of endothelial dysfunction compared with standard therapy alone in T2DM patients without ASCVD or severe TOD but with SCORE2-Diabetes ≥10%. [From enrollment to the end of treatment at 52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.